229 related articles for article (PubMed ID: 34844776)
1. Sequential modulation of the Wnt/β-catenin signaling pathway enhances tumor-intrinsic MHC I expression and tumor clearance.
Dholakia J; Scalise CB; Katre AA; Goldsberry WN; Meza-Perez S; Randall TD; Norian LA; Novak L; Arend RC
Gynecol Oncol; 2022 Jan; 164(1):170-180. PubMed ID: 34844776
[TBL] [Abstract][Full Text] [Related]
2. Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
Wall JA; Meza-Perez S; Scalise CB; Katre A; Londoño AI; Turbitt WJ; Randall T; Norian LA; Arend RC
Gynecol Oncol; 2021 Jan; 160(1):285-294. PubMed ID: 33168307
[TBL] [Abstract][Full Text] [Related]
3. E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling.
Yamada K; Hori Y; Inoue S; Yamamoto Y; Iso K; Kamiyama H; Yamaguchi A; Kimura T; Uesugi M; Ito J; Matsuki M; Nakamoto K; Harada H; Yoneda N; Takemura A; Kushida I; Wakayama N; Kubara K; Kato Y; Semba T; Yokoi A; Matsukura M; Odagami T; Iwata M; Tsuruoka A; Uenaka T; Matsui J; Matsushima T; Nomoto K; Kouji H; Owa T; Funahashi Y; Ozawa Y
Cancer Res; 2021 Feb; 81(4):1052-1062. PubMed ID: 33408116
[TBL] [Abstract][Full Text] [Related]
4. Wnt/beta-catenin pathway: modulating anticancer immune response.
Pai SG; Carneiro BA; Mota JM; Costa R; Leite CA; Barroso-Sousa R; Kaplan JB; Chae YK; Giles FJ
J Hematol Oncol; 2017 May; 10(1):101. PubMed ID: 28476164
[TBL] [Abstract][Full Text] [Related]
5. Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors.
Huang T; Li F; Cheng X; Wang J; Zhang W; Zhang B; Tang Y; Li Q; Zhou C; Tu S
Front Immunol; 2021; 12():619209. PubMed ID: 33790893
[TBL] [Abstract][Full Text] [Related]
6. WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment.
Li X; Xiang Y; Li F; Yin C; Li B; Ke X
Front Immunol; 2019; 10():2293. PubMed ID: 31616443
[TBL] [Abstract][Full Text] [Related]
7. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
[No Abstract] [Full Text] [Related]
8. Biomimetic and Self-Assembled Nanoclusters Targeting β-Catenin for Potent Anticancer Therapy and Enhanced Immunotherapy.
Liu J; Yan J; Yan S; Wang Y; Zhang R; Hou P; He W; Ji M
Nano Lett; 2019 Dec; 19(12):8708-8715. PubMed ID: 31744296
[TBL] [Abstract][Full Text] [Related]
9. Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy.
Zhang C; Zhang Z; Zhang S; Wang W; Hu P
Med Sci Monit; 2017 Jan; 23():266-275. PubMed ID: 28090074
[TBL] [Abstract][Full Text] [Related]
10. RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade.
Ganesh S; Shui X; Craig KP; Park J; Wang W; Brown BD; Abrams MT
Mol Ther; 2018 Nov; 26(11):2567-2579. PubMed ID: 30274786
[TBL] [Abstract][Full Text] [Related]
11. Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape.
Takeuchi Y; Tanegashima T; Sato E; Irie T; Sai A; Itahashi K; Kumagai S; Tada Y; Togashi Y; Koyama S; Akbay EA; Karasaki T; Kataoka K; Funaki S; Shintani Y; Nagatomo I; Kida H; Ishii G; Miyoshi T; Aokage K; Kakimi K; Ogawa S; Okumura M; Eto M; Kumanogoh A; Tsuboi M; Nishikawa H
Sci Immunol; 2021 Nov; 6(65):eabc6424. PubMed ID: 34767457
[TBL] [Abstract][Full Text] [Related]
12. Combretastatin A-1 phosphate, a microtubule inhibitor, acts on both hepatocellular carcinoma cells and tumor-associated macrophages by inhibiting the Wnt/β-catenin pathway.
Mao J; Wang D; Wang Z; Tian W; Li X; Duan J; Wang Y; Yang H; You L; Cheng Y; Bian J; Chen Z; Yang Y
Cancer Lett; 2016 Sep; 380(1):134-43. PubMed ID: 27349166
[TBL] [Abstract][Full Text] [Related]
13. Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models.
Waaler J; Mygland L; Tveita A; Strand MF; Solberg NT; Olsen PA; Aizenshtadt A; Fauskanger M; Lund K; Brinch SA; Lycke M; Dybing E; Nygaard V; Bøe SL; Heintz KM; Hovig E; Hammarström C; Corthay A; Krauss S
Commun Biol; 2020 Apr; 3(1):196. PubMed ID: 32332858
[TBL] [Abstract][Full Text] [Related]
14. Disruption of Wnt/β-catenin Pathway Elevates the Sensitivity of Gastric Cancer Cells to PD-1 Antibody.
Li J; Zhang H; Bei S; Zhang X; Li H; Ye L; Feng L
Curr Mol Pharmacol; 2022; 15(3):557-569. PubMed ID: 34139974
[TBL] [Abstract][Full Text] [Related]
15. TRIB3 Interacts With β-Catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and Tumorigenesis.
Hua F; Shang S; Yang YW; Zhang HZ; Xu TL; Yu JJ; Zhou DD; Cui B; Li K; Lv XX; Zhang XW; Liu SS; Yu JM; Wang F; Zhang C; Huang B; Hu ZW
Gastroenterology; 2019 Feb; 156(3):708-721.e15. PubMed ID: 30365932
[TBL] [Abstract][Full Text] [Related]
16. Intrinsic β-catenin signaling suppresses CD8
Xue J; Yu X; Xue L; Ge X; Zhao W; Peng W
Biomed Pharmacother; 2019 Jul; 115():108921. PubMed ID: 31078045
[TBL] [Abstract][Full Text] [Related]
17. Blocking Wnt/β-catenin Signal Amplifies Anti-PD-1 Therapeutic Efficacy by Inhibiting Tumor Growth, Migration, and Promoting Immune Infiltration in Glioblastomas.
Zhang H; Bi Y; Wei Y; Liu J; Kuerban K; Ye L
Mol Cancer Ther; 2021 Jul; 20(7):1305-1315. PubMed ID: 34001635
[TBL] [Abstract][Full Text] [Related]
18. Raddeanin A inhibits growth and induces apoptosis in human colorectal cancer through downregulating the Wnt/β-catenin and NF-κB signaling pathway.
Wang Y; Bao X; Zhao A; Zhang J; Zhang M; Zhang Q; Ma B
Life Sci; 2018 Aug; 207():532-549. PubMed ID: 29972765
[TBL] [Abstract][Full Text] [Related]
19. WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers.
Luke JJ; Bao R; Sweis RF; Spranger S; Gajewski TF
Clin Cancer Res; 2019 May; 25(10):3074-3083. PubMed ID: 30635339
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974.
Boone JD; Arend RC; Johnston BE; Cooper SJ; Gilchrist SA; Oelschlager DK; Grizzle WE; McGwin G; Gangrade A; Straughn JM; Buchsbaum DJ
Lab Invest; 2016 Feb; 96(2):249-59. PubMed ID: 26658453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
